Bert Klebl PhD

Bert Klebl is the LDC´s Managing Director and Chief Scientific Officer. Bert has gathered more than 20 years of professional experience in the life sciences industry. He has worked in different positions in drug discovery and early development, most recently as Senior Director of Discovery Biology and Head of Biology at GPC Biotech. Before that, he was Axxima’s Vice President of Research responsible for the discovery and development of the company’s portfolio of kinase inhibitors for various therapeutic indications. In previous positions, he has worked as a project and platform manager, as well as a scientist at Aventis and Hoechst Marion Roussel. He earned his Ph.D. in biochemistry at the University of Konstanz, Germany, and did postdoctoral work at the NRC Biotechnology Research Institute in Montréal, Canada. In the course of his research, he has published more than 55 articles in peer-reviewed journals and co-invented more than 25 patents and patent applications.

Within the Antihelix consortium, he has a role as principal investigator, is a member of the Supervisory Board, and leader of work package 4. As head of the Exploitation Committee, he is overseeing the identification of ideas, products, and technologies with commercial utilization potential.